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Introduction: Rosuvastatin (ROS) calcium is the latest synthetic drug in the statin 
group that has an anti-hyperlipidemic activity. It is available as tablets, and its poor 
aqueous solubility, slow dissolution rate and low-absorption extent result in less than 
20% bioavailability and about 80% being excreted unchanged in the feces without 
absorption. The present study aimed at developing an optimal oral nanoemulsion 
formulation containing rosuvastatin using different proportions of oil and surfactant 
system for enhancing its water solubility and bioavailability. 
Methods and results: The solubility of ROS in different oils, surfactants and co-
surfactants was tested. Based on the solubility study, liquid formulations were 
prepared using Arachis oil as oil phase and Tween 80 as surfactant and polyethylene 
400 as co-surfactant. Pseudo-ternary phase diagrams were developed and various 
nanoemulsion formulations were prepared and evaluated for globule size, zeta 
potential, and emulsion properties. The formulations were subjected to different 
thermodynamic stability studies such as centrifugation, heating-cooling cycle and 
freeze-thaw cycle, to avoid the selection of metastable formulations. Transmittance 
study and in-vitro dissolution studies were carried out. An optimal nanoemulsion 
system was successfully developed with the droplet size of 260 nm and a 
composition of (Arachis oil; 20%), Tween 80 (40%) and PEG 400 (40%). The 
cumulative percentage drug release from optimal nanoemulsion formulation was 
found to be 93.29±1.11% for 50 minutes, which was significantly higher than the 
drug suspension (43.42±1.30%). Thus, in vitro results reveal that the prepared 
nanoemulsion formulations showed improved solubility of ROS. 
Conclusions: Nanoemulsion formulations of ROS represent a promising novel 
formula with a higher dissolution rate when compared to the drug in suspension.   
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